KTC
ONCE

Kistler-Tiffany Companies’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Kistler-Tiffany Companies’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-370
Closed -$19K – 600
2017
Q4 		$19K Hold
370
– – 0.01% 381
2017
Q3 		$33K Buy
+370
New +$28.1K 0.01% 321

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kistler-Tiffany Companies's ONCE Position: Q1 2018 in Review

Kistler-Tiffany Companies sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2018, closing a stake of 370 shares — an estimated $19K sold.

Kistler-Tiffany Companies first reported a position in ONCE in Q3 2017 and held it in 2 quarters. The position peaked at $33K in Q3 2017. 162 funds tracked by Wall St. Rank hold ONCE as of Q1 2018.

  • Kistler-Tiffany Companies reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 370 Spark Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $19K.
  • Kistler-Tiffany Companies first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Kistler-Tiffany Companies's Spark Therapeutics, Inc. Common Stock position peaked at $33K in Q3 2017.
  • 162 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Kistler-Tiffany Companies's 13F filing for Q1 2018, filed 6 Apr 2018.